[go: up one dir, main page]

PE20120318A1 - 17ß-ALQUIL-17A-OXI-ESTRATRIENOS - Google Patents

17ß-ALQUIL-17A-OXI-ESTRATRIENOS

Info

Publication number
PE20120318A1
PE20120318A1 PE2011002048A PE2011002048A PE20120318A1 PE 20120318 A1 PE20120318 A1 PE 20120318A1 PE 2011002048 A PE2011002048 A PE 2011002048A PE 2011002048 A PE2011002048 A PE 2011002048A PE 20120318 A1 PE20120318 A1 PE 20120318A1
Authority
PE
Peru
Prior art keywords
alkyl
alkylene
alkenyl
beta
compounds
Prior art date
Application number
PE2011002048A
Other languages
English (en)
Inventor
Dieter Lang
Rolf Bohlmann
Nikolaus Heinrich
Jan Hubner
Hermann Kunzer
Philip Lienau
Michael Gerisch
Silke Kohr
Karsten Denner
Michael Sander
Jens Hoffmann
Tim Wintermantel
Georg Kattschau
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41460961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120318(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20120318A1 publication Critical patent/PE20120318A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 17?-ALQUIL-17?-OXI-ESTRATRIENOS DE FORMULA (I) DONDE HAL ES FLUOR O CLORO; R1, R2 Y R4 SON CADA UNO H, FLUOR, CLORO O BROMO; R3 ES H, ALQUILO(C1-C4) O ALCANILO(C1-C4); R17' ES H, ALQUILO(C1-C4) O ALCANILO(C1-C4); R17'' ES ALQUILO(C1-C4), ALQUENILO(C2-C4) O ALQUINILO(C2-C4); U ES ALQUILENO(C1-C13), ALQUENILENO(C2-C13), ENTRE OTROS; V ES METILENO O -C(O)-; X ES UN ENLACE O ALQUILENO(C1-C3); Y ES ALQUILENO(C5-C8); E ES PERFLUOROALQUILO(C1-C4) O FENILO SUSTITUIDO CON HALOGENO O CF3; R5 ES H, ALQUILO(C1-C4), ALQUENILO(C2-C4), ENTRE OTROS; R6 ES H, CH2-R1 O C(O)-R1, EN DONDE R1 ES H, ALQUENILO(C2-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: [5-(11?-FLUORO-3,17?-DIHIDROXI-17?-METILESTRA-1,3,5(10)-TRIEN-7?-IL)PENTIL](METIL)(8,8,9,9,9-PENTAFLUORONONIL)AMINA; 11?-FLUORO-17?-METIL-7?-[5-[(2R)-2-(7,7,8,8,8-PENTAFLUOROOCTIL)-1-PIRROLIDINIL]PENTIL]-ESTRA-1,3,5(10)-TRIENO-3,17?-DIOL; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACCION ANTIESTROGENICA SIENDO UTILES EN EL TRATAMIENTO DE TUMORES DEPENDIENTES DE HORMONAS, ALOPECIA DIFUSA, ENDOMETRIOSIS
PE2011002048A 2009-06-04 2010-05-26 17ß-ALQUIL-17A-OXI-ESTRATRIENOS PE20120318A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09075249A EP2258375A1 (de) 2009-06-04 2009-06-04 17B-alkyl-17alpha-oxy-estratriene

Publications (1)

Publication Number Publication Date
PE20120318A1 true PE20120318A1 (es) 2012-03-24

Family

ID=41460961

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002048A PE20120318A1 (es) 2009-06-04 2010-05-26 17ß-ALQUIL-17A-OXI-ESTRATRIENOS

Country Status (27)

Country Link
US (1) US20120157421A1 (es)
EP (2) EP2258375A1 (es)
JP (1) JP2012528808A (es)
KR (1) KR20120042827A (es)
CN (1) CN102802634A (es)
AR (1) AR076980A1 (es)
AU (1) AU2010256035A1 (es)
BR (1) BRPI1013017A2 (es)
CA (1) CA2764249A1 (es)
CL (1) CL2011003050A1 (es)
CO (1) CO6470855A2 (es)
CR (1) CR20110647A (es)
CU (1) CU20110224A7 (es)
DO (1) DOP2011000374A (es)
EA (1) EA201101703A1 (es)
EC (1) ECSP11011501A (es)
IL (1) IL216524A0 (es)
MA (1) MA33329B1 (es)
MX (1) MX2011012878A (es)
NZ (1) NZ596824A (es)
PE (1) PE20120318A1 (es)
SG (1) SG176630A1 (es)
TN (1) TN2011000617A1 (es)
TW (1) TW201103547A (es)
UY (1) UY32688A (es)
WO (1) WO2010139411A2 (es)
ZA (1) ZA201200036B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116041412A (zh) * 2023-01-13 2023-05-02 香港中文大学（深圳） 氟维司群衍生物及其制备方法、应用和治疗乳腺癌的药物
CN116535454A (zh) * 2023-04-28 2023-08-04 香港中文大学（深圳） 氟维司群类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
EP0310542B1 (de) 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
DE19510862A1 (de) 1995-03-16 1996-09-19 Schering Ag Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle
DE19622457A1 (de) 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
AR015500A1 (es) 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
DE10019171A1 (de) 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate

Also Published As

Publication number Publication date
CN102802634A (zh) 2012-11-28
DOP2011000374A (es) 2012-01-15
MA33329B1 (fr) 2012-06-01
CL2011003050A1 (es) 2012-06-15
CA2764249A1 (en) 2010-12-09
AU2010256035A1 (en) 2011-12-22
IL216524A0 (en) 2012-02-29
EP2437746A2 (de) 2012-04-11
CO6470855A2 (es) 2012-06-29
ZA201200036B (en) 2013-06-26
NZ596824A (en) 2013-07-26
UY32688A (es) 2010-12-31
MX2011012878A (es) 2012-01-12
US20120157421A1 (en) 2012-06-21
TW201103547A (en) 2011-02-01
JP2012528808A (ja) 2012-11-15
KR20120042827A (ko) 2012-05-03
EA201101703A1 (ru) 2012-06-29
AR076980A1 (es) 2011-07-20
WO2010139411A3 (de) 2011-03-10
CU20110224A7 (es) 2012-04-15
CR20110647A (es) 2012-02-16
WO2010139411A2 (de) 2010-12-09
BRPI1013017A2 (pt) 2016-03-29
TN2011000617A1 (en) 2013-05-24
SG176630A1 (en) 2012-01-30
ECSP11011501A (es) 2012-01-31
EP2258375A1 (de) 2010-12-08

Similar Documents

Publication Publication Date Title
PE20090641A1 (es) Amidas heterociclicas
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
AR078462A1 (es) Inhibidores macrociclicos de la replicacion de virus de la hepatitis c
PE20120008A1 (es) Derivados de fenoxi bencenosulfonamida
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20110416A1 (es) Compuestos de piperidina puenteada tipo quinoxalina sustituida con actividad sobre el receptor orl-1
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20140207A1 (es) Composiciones y metodos para modular el fxr
PE20141702A1 (es) Compuestos de carbamato y preparacion y uso de los mismos
PE20091816A1 (es) Inhibidores de bace
PE20141685A1 (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
PE20141597A1 (es) Triazolopiridinas sustituidas
DOP2010000326A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
PE20141943A1 (es) Antagonistas de trpv4
PE20130683A1 (es) Ariltriazolonas ligadas a bisarilo y su uso
PE20110547A1 (es) Compuestos de isoindolina con actividad anticancerigena
PE20081447A1 (es) Compuestos y composiciones como inhibidores de la proteina cinasa
PE20120305A1 (es) Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl
PE20071022A1 (es) Compuestos derivados de dibencilamina como inhibidores de la proteina de transferencia del colesteril ester (cept)
NI200800008A (es) Métodos para la neuroprotección
PE20140792A1 (es) Composiciones farmaceuticas
CY1116190T1 (el) Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην

Legal Events

Date Code Title Description
FD Application declared void or lapsed